Safety and Efficiency of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT: a Prospective, Single-arm, Single-center, Phase II Study.
Safety and Efficiency of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT: a Prospective, Single-arm, Single-center, Phase II Study. is a PHASE2 clinical asset sponsored by Institute of Hematology & Blood Diseases Hospital, China in Multiple Myeloma. SEO and diligence focus: anti-BCMA CAR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Multiple Myeloma
Modality: cell therapy
Target: anti-BCMA CAR-T
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: anti-BCMA CAR-T
View original source fields
Condition raw: Multiple Myeloma
Condition normalized: Multiple Myeloma
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: anti-BCMA CAR-T
Target normalized: anti-BCMA CAR-T